Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Background: HER2 overexpression/amplification in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) may be associated with resistance to standard-of-care anti-EGFR therapies. Given the lack of comprehensive investigations into this association, we assessed the prognostic or predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes. Methods: A systematic review of MEDLINE, Embase, and Cochrane Library (2001-2021) identified studies evaluating progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) in HER2-positive vs. HER2-negative patients with RAS WT mCRC who received anti-EGFR treatments and whose HER2 status was known. Meta-analyses of proportions (ORR) and hazard ratios (PFS, OS) were performed using random-effect models with pre-specified sensitivity analyses. Results: Five high-quality retrospective cohort studies were included in the meta-analyses representing 594 patients with mCRC. All patients received anti-EGFR treatment, either as monotherapy or in combination with chemotherapy. Meta-analysis of PFS demonstrated a 2.84-fold higher risk of death or progression (95% CI, 1.44-5.60) in patients with HER2-positive (vs. HER2-negative) RAS WT mCRC treated with anti-EGFR regimens. The odds of response to anti-EGFR treatment were 2-fold higher in HER2-negative vs. HER2-positive (odds ratio, 1.96 [95% CI, 1.10-3.48]). Differences in OS were not statistically significant. Sensitivity analyses confirmed the robustness of the base-case estimates. Conclusions: While this study could not account for all confounding factors, in patients with RAS WT mCRC who received anti-EGFR therapy, HER2 overexpression/amplification was associated with worse PFS and ORR and may therefore predict poorer outcomes. HER2 testing is important to inform treatment decisions and could optimize outcomes for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2 is overexpressed in 3–5% of mCRC [31], and HER2 amplification is associated with lower incidence of activating KRAS mutations and occurs more commonly in left-sided CRC tumors.”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [31]
In the citing paper
“HER2 overexpression is a negative predictor associated with reduced efficacy of anti-EGFR therapy [31], and >36% of cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
A note on graphical presentation of estimated odds ratios from several clinical trials
Galbraith, R. F. (1988) · Statistics in Medicine · doi:10.1002/sim.4780070807 · Cited by 663
Research works printed but not linked: 1
- Kang, 2021, Systematic literature review of HER2 amplification/overexpression in colorectal cancer, J Manag Care Spec Pharm, 27, C6
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
Ciracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 53
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
HER2-targeted therapy in colorectal cancer: a comprehensive review
Benli, Y., Arıkan, H., & Akbulut, Ö. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03887-0 · Cited by 30
Treatment options for HER2-expressing colorectal cancer: updates and recent approvals
Zheng-Lin, B., & Bekaii‐Saab, T. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225037 · Cited by 27
Self-citationTreatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies
Tarpgaard, L. S., Winther, S. B., & Pfeiffer, P. (2023) · Cancers · doi:10.3390/cancers16010126 · Cited by 12
Targeting the MAP Kinase Pathway in Colorectal Cancer: A Journey in Personalized Medicine
Appleyard, J. W., Williams, C. J. M., Manca, P., Pietrantonio, F., & Seligmann, J. F. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0107 · Cited by 11
Agüera-Sánchez, A., Ros, E. P., Martínez‐Martínez, I., & García-Molina, F. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16010048 · Cited by 9
Bekaii‐Saab, T. (2024) · The American Journal of Managed Care · doi:10.37765/ajmc.2024.89545 · Cited by 11
Self-citationSpiró, Z., Amin, E.-H., Mair, M. J., Pieber, T. R., Prietl, B., Spiegl‐Kreinecker, S., Stanzer, S., Wöhrer, A., Preusser, M., & Berghoff, A. S. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103072 · Cited by 8
Hoyek, C., Zheng-Lin, B., Jones, J. C., & Bekaii‐Saab, T. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472411 · Cited by 6
Self-citationSequencing considerations in the third-line treatment of metastatic colorectal cancer
Barzi, A., & Bekaii‐Saab, T. (2024) · The American Journal of Managed Care · doi:10.37765/ajmc.2024.89546 · Cited by 7
Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries
Shouki, B., Abdelsalam, A., Abdullah, A. S., Alshammari, K. M., Ahmed, A. M., Dawoud, E., Heinemann, V., Mohamed, A., Chehal, A. A., Mohammed, A., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241299324 · Cited by 6
Camera, S., Rimini, M., Foti, S., Prinzi, F. L., Vitiello, F., Amadeo, E., Persano, M., Cascinu, S., Gardini, A. C., & Rossari, F. (2025) · Oncology · doi:10.1159/000545308 · Cited by 4
EGFR-targeted therapies based on antibody engineering and nanotechnology for colorectal cancer
Shang, X., Zhang, Z., Wu, T., Nan, Y., & Ju, D. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124210 · Cited by 4
Voutsadakis, I. A. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2479414 · Cited by 4
Siena, S., Chalabi, M., Goodwin, R. A., Osterlund, P. J., Penault-Llorca, F. M., Sartore-Bianchi, A., Starling, N., Stintzing, S., & Tabernero, J. M. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103097 · Cited by 4
Systemic Therapy for Metastatic Colon Cancer: New Frontiers
Pumpalova, Y. S. (2024) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0044-1787826 · Cited by 2
Pang, H., Yan, M.-Y., Chen, X., & Sun, H. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.07.136 · Cited by 2
Bianchi, A. S., Marsoni, S., Amatu, A., Torri, V., Bonoldi, E., Bardelli, A., Trusolino, L., & Siena, S. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00805 · Cited by 2
Jia, Y., Li, X. Y., Chen, D., Wu, L., Zeng, Y., & Qin, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1714422 · Cited by 1
Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives
Ismail, M., Al‐Gizey, N., Al-Najjar, E., Alabed, Z., Mustafa, N., Hamdaneh, Y., & Esmail, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1927829 · Cited by 1
Biopsie colique et pathologie néoplasique épithéliale en pratique
Chatelain, D. (2023) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(24)00014-5
Current treatment options of HER2+ metastatic colorectal carcinoma
Liberko, M., & Soumarová, R. (2024) · Onkologie · doi:10.36290/xon.2024.039
Reply to A. Sartore-Bianchi et al
Battaglin, F., Ou, F., Innocenti, F., & Lenz, H. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01086
An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer
Mo, C., Chadha, B., & Kuang, C. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.08.003 · Cited by 3
Advancement in therapeutic approach for treatment of metastatic colorectal cancer
Shreya, S., N, R. B., Kancharla, S., Kolli, P., Mandadapu, G., & Jena, M. K. (2025) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2025.033.2.22
Tang, W., Zheng, H., Wang, Q., Zhang, X., Zhou, S., Ge, C., & Fu, J. (2025) · Case Reports in Oncology · doi:10.1159/000549570
Matsubara, Y., Bando, H., Nakamura, Y., Misumi, T., Ng, D., Tajima, E., Pittell, H., Ohtsu, A., & Yoshino, T. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03270-4
HER2 in Metastatic Colorectal Cancer: Diagnostic and Therapeutic Opportunities and Challenges
Zhao-Tao, P. A. N., Feng-Yu, G. A. I., Chen, C., Tong, L. I., & Yan-Ping, Q. I. N. G. (2026) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/j.pibb.2025.0480
Михайловна, Б. М., Antonova, T. G., Лебедева, А. А., Kavun, A., Кошкина, К. Д., Taraskina, A. N., Belova, E., Алексеевна, К. О., Милейко, В. А., Сергеевна, К. Е., et al. (2026) · Voprosy Onkologii · doi:10.37469/0507-3758-2026-72-2-of-2491
Özdemir, Ö., Günenç, D., Taşkaynatan, H., Peker, P., Kahraman, E. G., Biter, S., Paydaş, S., Önder, T., Ateş, Ö., Er, M. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103979
Gandini, A., Tosi, F., Carmisciano, L., Grillo, F., Mastracci, L., Puglisi, S., Pirrone, C., Nardin, S., Martelli, V., Pastorino, A., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-56380-1
Rota, S., Nardo, P. D., Zottarelli, E., Giudici, F., Vida, R., Zilli, M., de Scordilli, M., Foltran, L., Fumagalli, A., Guardascione, M., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag224
Zhou, K., & Yu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1925363
Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer
Hamabe, A., Suwa, Y., Hirata, K., Akazawa, N., Hirata, K., Ikeda, M., Yokota, M., Kato, K., Kotaka, M., Nishizawa, Y., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03161-5
Sagawa, T., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01564-1
Metadata
- Authors
- Bekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H.
- Affiliations
- Division of Hematology/Oncology, Mayo Clinic , Phoenix, AZ , USA
- Maple Health Group, LLC , New York, NY , USA
- Seagen (United States) (US)
- Duke Medical Center (US)
- Corresponding author
- Strickler, John H
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- Volume
- 28
- Issue
- 10
- Pages
- 885-893
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC10546818
- OpenAlex
- W4384625387
- Cited by
- 36
- References
- 34
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 12 · 2023: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Oncologist (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Seagen Inc
- Merck Sharp & Dohme Corp
- Merck & Co., Inc
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- HER2 overexpression, HER2 amplification, metastatic colorectal cancer, RAS wild-type, anti-EGFR therapy, progression-free survival, overall response rate, overall survival, predictive biomarkers, HER2 testing, treatment resistance
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Rectal Neoplasms, Retrospective Studies, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.